Sanofi completes acquisition of Vigil Neuroscience for $8.00/sh + CVR

Vigil Neuroscience, Inc.

Merger closed Aug 5, 2025; each share of VIGL converted to $8.00 cash plus one CVR.
CVR entitles holder to $2.00 per CVR upon first commercial sale of VG-3927 for Alzheimer's.
Stockholders voted 35,191,885 for, 9,521 against, 133,827 abstain to adopt merger.
All directors and officers resigned; replaced by designees of Sanofi.
VIGL common stock trading halted; delisting and deregistration initiated.

item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Vigil Neuroscience, Inc.: Certificate of incorporation amended and restated in its entirety pursuant to the Merger Agreement.

Change: charter amendment

Exact text from the filing

Pursuant to the Merger Agreement, at the Effective Time, Vigil’s certificate of incorporation was amended and restated in its entirety.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-25-173134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.